Telomir reports peer-reviewed study: Telomir-Zn restores retinal structure/function in AMD model

Telomir Pharmaceuticals, Inc.

Telomir-Zn restored visual function and retinal structure after 14 days oral treatment in zebrafish AMD model; published in Int. J. Mol. Sci. 2026, 27(18), 8265.
Treatment reduced mitochondrial oxidative stress and restored thickness across multiple retinal layers including outer/inner nuclear, outer plexiform, and ganglion cell layers.
Telomir-Zn inhibited Fe²⁺-dependent Jumonji C histone demethylases across KDM2/KDM5/KDM6 families, strongest against KDM5B (IC50 63 nM).
Dose-dependent increase in relative telomeric DNA content toward wild-type profile and restoration of DNA methylation at aging-associated CpG loci.
Clinical priority remains oncology: FDA-cleared Phase 1/2 trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.